Merck: receives ACIP recommendation for Enflonsia

Published: 2025-06-27 05:37:57 ET MRK

Published on 06/27/2025 at 05:37

Merck announces that the CDC's Advisory Committee on Immunization Practices (ACIP) has voted in favor of recommending Enflonsia (clesrovimab-cfor) for the prevention of respiratory infections caused by RSV in infants under 8 months of age during their first season at risk. The product is also being added to the Vaccines for Children program to expand access. Recently approved by the FDA, it is based on data from the CLEVER (Phase 2b/3) and SMART (Phase 3) clinical studies. Merck expects it to be available for order in July 2025. The ACIP's recommendation remains provisional pending approval by the relevant health authorities.Copyright (c) 2025 CercleFinance.com. All rights reserved.